Evotec (NASDAQ:EVO) Shares Gap Up – Here’s What Happened

Evotec SE (NASDAQ:EVO) shares gapped up before the market opened on Monday . The stock had previously closed at $4.44, but opened at $4.58. Evotec shares last traded at $4.45, with a volume of 39,766 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Evotec in a research note on Thursday, November 7th.

Evotec Trading Up 1.1 %

The company’s 50 day moving average price is $4.41 and its 200 day moving average price is $4.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.

Hedge Funds Weigh In On Evotec

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Evotec in the fourth quarter valued at approximately $27,000. CSS LLC IL acquired a new position in Evotec in the fourth quarter valued at approximately $50,000. Bank of America Corp DE raised its holdings in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in Evotec in the third quarter worth $104,000. Finally, Lighthouse Investment Partners LLC acquired a new stake in Evotec in the fourth quarter worth $166,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.